MIR371A

Summary

MIR371A (microRNA 371a, HGNC:31785) is a microRNA gene on chromosome 19q13.42.

microRNAs (miRNAs) are short (20-24 nt) non-coding RNAs that are involved in post-transcriptional regulation of gene expression in multicellular organisms by affecting both the stability and translation of mRNAs. miRNAs are transcribed by RNA polymerase II as part of capped and polyadenylated primary transcripts (pri-miRNAs) that can be either protein-coding or non-coding. The primary transcript is cleaved by the Drosha ribonuclease III enzyme to produce an approximately 70-nt stem-loop precursor miRNA (pre-miRNA), which is further cleaved by the cytoplasmic Dicer ribonuclease to generate the mature miRNA and antisense miRNA star (miRNA*) products. The mature miRNA is incorporated into a RNA-induced silencing complex (RISC), which recognizes target mRNAs through imperfect base pairing with the miRNA and most commonly results in translational inhibition or destabilization of the target mRNA. The RefSeq represents the predicted microRNA stem-loop.

Source: NCBI Gene 442916 — RefSeq curated summary.

At a glance

• Gene type: non-coding (miRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:31785
Approved symbol	MIR371A
Name	microRNA 371a
Location	19q13.42
Locus type	RNA, micro
Status	Approved
Aliases	hsa-mir-371
Ensembl gene	ENSG00000199031
Ensembl biotype	miRNA
OMIM	612043
Entrez	442916
RNAcentral	URS000075E7B1 — miRNA, 67 nt, 7 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 miRNA

ENST00000362161

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000362161 — 1 exons

Exon	Start	End
ENSE00001436924	53787675	53787741

Expression profiles

Bgee: expression breadth tissue_specific, 4 present calls, max score 84.24.

Top tissues by expression

4 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	84.24	gold quality
blood	UBERON:0000178	70.49	gold quality
ascending aorta	UBERON:0001496	68.80	gold quality
spleen	UBERON:0002106	62.98	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	0.00

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 40)

• two stem cell microRNA gene clusters C19MC (miR-512-5p, miR-517a, and miR-519a)and miR-371-3 are activated by specific chromosomal rearrangements in a subgroup of thyroid adenomas (PMID:20209130)
• The miR-371-3 expression level therefore appears to have both a predictive and a functional role in determining human pluripotent stem cell neurogenic differentiation behavior. (PMID:21624813)
• miR-369-5p and miR-371 as antagonistic up-stream regulators of adipogenic differentiation and this might be indirectly mediated by epigenetic modifications. (PMID:21660946)
• study demonstrated that one pri-miRNAs-371-373 polymorphism (rs3859501 C>A) and the pri-miRNAs-371-373_ht2 [C-A-C] haplotype were more protective to hepatocellular carcinoma (HCC) occurrence in patients with HBV infection; the polymorphism of pri-miRNAs-371-373 was not associated with spontaneous HBV clearance (PMID:22848681)
• data indicate that miR-371-5p, which is highly expressed in hepatocellular carcinoma, promotes the growth of HCC cells in vitro and in vivo by activating cell cycle progression at the G1/S checkpoint by directly targeting PRPF4B (PMID:23466643)
• Targeted serum miRNA (TSmiR) test for diagnosis and follow-up of (testicular) germ cell cancer patients: a proof of principle. (PMID:24012110)
• onco-miR-372-373 has a role in testicular germ cell tumours; its imprinted antisense transcript anti-miR-371-3 has a tumour suppressive role (PMID:24201333)
• As a result, miR-200c and miR-371-5p were significantly upregulated in the Kawasaki disease group compared with the control group (PMID:24259014)
• Serum levels of miR-371a-3p appear to be a promising specific biomarker of germ cell tumors as is suggested by high serum levels in GCT patients, and the rapid return of elevated levels to normal range after treatment. (PMID:25187505)
• Results showed that expression level of miR-371-5p was dramatically upregulated in pancreatic duct adenocarcinoma tissues and correlated with significantly shorter survival. Also, its expression is regulated by ING1. (PMID:25411783)
• miR-371-5p is an important “oncosuppressor” in CRC progression. A novel mechanism of the SOX17/miR-371-5p/SOX2 axis is involved in the regulation of EMT, stemness and metastasis. (PMID:25868860)
• A serum/CSF miRNA panel (miR-371a-3p, miR-372-3p, miR-373-3p and miR-367-3p) was sensitive and specific for diagnosing pediatric extracranial malignant GCT as well as detecting relapse, and distinguishing GCT vs. non-GCT intracranial neoplasms. (PMID:26671749)
• This study provides evidence for the origin of circulating miR 371a-3p molecules from germ cell tumor cells. miR-371a-3p represents a specific serum biomarker for germ cell cancer (PMID:26989896)
• These findings implicate miR-371-3p as a suppressor of PRDX6 and suggest that co-targeting of peroxiredoxin 6 or modulating miR-371-3p expression together with targeted cancer therapies may delay or prevent acquired drug resistance. (PMID:27484502)
• Elevated circulating miR371a-3p levels heralded undetected primary testicular GCT and metastases despite inconclusive radiological findings. (PMID:28586780)
• Collectively, our data strongly suggest that ATIIC-derived exosome miR-371b-5p may serve as a niche signaling to augment ATIIC survival/proliferation, promoting re-epithelialization of injured alveoli, and thus provide a promising novel target to develop treatment for currently incurable lung diseases. (PMID:28595637)
• At primary diagnosis the levels of miR-371a-3p was elevated in 4/4 testicular germ cell cancer (TGCC) patients. (PMID:28612337)
• High miR371a expression is associated with germ cell neoplasia in situ. (PMID:28819887)
• miR-371a-3p is Testicular germ cell tumours-specific and it might be clinically useful for early detection and disease monitoring. (PMID:29685967)
• Micro-RNA-371a-3p has a role in testicular germ cell tumors and may be a tumor marker (PMID:29698973)
• Results show that miR-371a levels in serum samples of patients with testicular germ cell tumor (TGCT) with proven recurrence were increased compared to those without evidence of disease. miR-371 seems to be a sensitive and potentially novel biomarker for detecting disease relapse in TGCT patients. (PMID:30321995)
• Data reveal the upregulation of miR-371a in gastric cancer (GC), proving it to be a potential prognosis biomarker for GC through integrated analyses. Functional assays demonstrate that miR-371a promotes GC cell growth and metastasis in vitro and in vivo. (PMID:30529155)
• Plasma miR-371a-3p levels were measured with the ampTSmiR test. (PMID:30536846)
• In healthy males, the germ cell compartment is the cellular origin of miR-371a-3p. (PMID:30786164)
• The expression of miR-371a-5p and XIAP in chorionic villi cells is greatly decreased in recurrent pregnancy loss. (PMID:30819044)
• Serum levels of microRNA (miR)-371a-3p are informative in both testicular seminomas and nonseminomas. (PMID:30875280)
• Authors found PTEN to be a direct target of miR-371. The overexpression or knockdown of PTEN exhibited the opposite effects from those of miR-371 on cell proliferation and migration. Study demonstrates that miR-371 promotes proliferation and metastasis in HCC by targeting PTEN. (PMID:30940319)
• seminal plasma miR-371a-3p levels of germ cell tumor patients were not different from controls; correlation with sperm concentration in ejaculate samples suggests the spermatozoa as possible source of miR-371a-3p production (PMID:31310058)
• miR-371a-3p, miR-373-3p and miR-367-3p: high miR levels at start of chemotherapy of Metastatic Testicular Germ Cell Cancers are associated with worse clinical outcome and can assist in early diagnosing of relapses. (PMID:31597402)
• Real-World Application of Pre-Orchiectomy miR-371a-3p Test in Testicular Germ Cell Tumor Management. (PMID:32856980)
• The expression of miRNA encoded by C19MC and miR-371-3 strongly varies among individual placentas but does not differ between spontaneous and induced abortions. (PMID:33034783)
• High Expression of microRNA-371a-3p in Cystic Fluid of Post-Chemotherapy Teratoma with Concurrent Normal Serum Levels in Patients with Non-Seminomatous Testicular Germ Cell Tumours. (PMID:33049748)
• Impact of circulating microRNA test (miRNA-371a-3p) on appropriateness of treatment and cost outcomes in patients with Stage I non-seminomatous germ cell tumours. (PMID:33124175)
• Integrated Expression of Circulating miR375 and miR371 to Identify Teratoma and Active Germ Cell Malignancy Components in Malignant Germ Cell Tumors. (PMID:33158661)
• Utility of Serum miR-371a-3p in Predicting Relapse on Surveillance in Patients with Clinical Stage I Testicular Germ Cell Cancer. (PMID:33288479)
• The Diagnostic Accuracy of miR-371a-3p for Testicular Germ Cell Tumors: A Systematic Review and Meta-Analysis. (PMID:33886084)
• Serum miR371 in testicular germ cell cancer before and after orchiectomy, assessed by digital-droplet PCR in a prospective study. (PMID:34341387)
• Associations of serum levels of microRNA-371a-3p (M371) with risk factors for progression in nonseminomatous testicular germ cell tumours clinical stage 1. (PMID:34775512)
• Detection of recurrences using serum miR-371a-3p during active surveillance in men with stage I testicular germ cell tumours. (PMID:34912073)
• Plasma Micro-RNA 371 Expression in Early-Stage Germ Cell Tumors: Are We Ready to Move Toward Biology-Based Decision Making? (PMID:36758194)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Mir293	ENSMUSG00000078035
mus_musculus	Mir292	ENSMUSG00000078041

Paralogs (1): MIR372 (ENSG00000199095)

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.